Humacyte, Inc. (HUMA) AI Stock Analysis

Humacyte, Inc. specializes in advancing the development and production of off-the-shelf, bioengineered human tissues designed to treat diseases across multiple therapeutic areas. Using its proprietary scientific technology platform, the company engineers human acellular vessels (HAVs) intended to be implanted into patients without triggering an immune rejection or foreign body response. Its portfolio targets vascular repair, reconstruction, and replacement markets, including vascular trauma, arteriovenous access for hemodialysis, peripheral arterial disease, and coronary artery bypass grafting. Humacyte is also developing HAVs for pediatric heart surgery and cellular therapies, including pancreatic islet cell transplantation for Type 1 diabetes.

Humacyte reported revenue of $2.0M in FY2025, reflecting revenue growth of 30.2% following $1.6M in FY2022 and $1.3M in FY2021. However, revenue registered a 4-year CAGR of -24.2% from FY2019, when revenue was $6.2M. Profitability remains deeply negative, with FY2025 gross margin at -736.5% and operating margin at -5271.7%. Research and development expense reached $69.3M in FY2025, contributing to a net income of -$40.8M and an EPS of -$0.26. For the trailing twelve months ending June 30, 2026, revenue stood at $2.1M with an operating margin of -6649.3% and EPS of -$0.51, while quarterly revenue growth was 34.9% year-over-year.

As of June 30, 2026, Humacyte held $79.9M in cash and short-term investments and $66.2M in total debt, resulting in net cash of $13.7M. Total assets stood at $138.1M against shareholders' equity of $31.3M, yielding a debt-to-equity ratio of 2.12. Short-term liquidity is supported by a current ratio of 6.21. In FY2025, capital expenditures were $884,000, while operating cash flow was -$105.0M and free cash flow was -$105.9M. Over the past five years, the company's share count increased 123.6%.

At a last close price of $0.43 on October 16, 2026, Humacyte has a market cap of $119.2M and an enterprise value of $142.7M. The stock trades at a price-to-sales multiple of 56.2x and an EV to revenue multiple of 67.3x, significantly above the median of its US-listed Healthcare peers price-to-sales ratio of 4.1x. Its forward P/E is 35.8x compared to 17.3x for the peer median. Over the past year, HUMA has declined 74.8%, while the S&P 500 (SPY) returned 16.8%. Over five years, the shares fell 95.8% compared to an 83.0% gain for the benchmark.

Wall Street coverage consists of 2 Strong Buy, 1 Buy, and 2 Hold ratings, with zero Sell or Strong Sell ratings. The mean price target is $1.62, representing an implied upside of 278.8% versus the last close of $0.43. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $3.5M and an EPS of -$0.40. For the next fiscal year, 4 analysts forecast revenue of $21.7M and an EPS of -$0.25. The company beat EPS estimates in 2 of the last 4 quarters, and its next earnings date is November 11, 2026.

This page is an AI-written research summary of Humacyte, Inc. (HUMA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: HUMA income statement, HUMA balance sheet, HUMA key metrics, HUMA analyst forecast, HUMA chart. See the HUMA stock overview for the latest quote and news.